论文部分内容阅读
慢性肝病的药物治疗进展甚微。现已证实,可治疗性的慢性肝病为威尔逊氏病、自身免疫性慢活动性肝病及慢性活动性乙型肝炎;难以治疗的有原发性硬变性胆管炎、原发性胆硬变、酒精性肝炎和肝纤维化。本文对近四年来发表的有关慢性肝病治疗的文章加以综述,评价不同治疗方案的临床效果,并尽可能对未来的治疗提供可行性资料和谋略。威尔逊氏病(肝豆状核变性) 据认为,D-青霉胺是威尔逊氏病的主要治疗药物,对症状和存活率有显著改善作用,但长期应用有10%以上的病人不耐受,若每日维持量≤1g时则副作用少见。
Progress in the treatment of chronic liver disease is minimal. It has been confirmed that treatable chronic liver disease is Wilson’s disease, autoimmune slow active liver disease and chronic active hepatitis B; difficult to treat with primary cirrhosis cholangitis, primary biliary cirrhosis, alcohol Hepatitis and liver fibrosis. This article reviews the articles published in the past four years on the treatment of chronic liver disease, evaluate the clinical effects of different treatment options, and provide feasible data and strategies for future treatment as far as possible. Wilson’s disease (Wilson’s disease) It is thought that D-penicillamine is the mainstay of treatment for Wilson’s disease and has a significant improvement in symptoms and survival rates. However, over 10% of patients are intolerant for long-term use, If the daily maintenance dose ≤ 1g side effects are rare.